Loading...
Market
What major milestone will Sarepta and Arrowhead achieve by end of 2025?
3
Resolution / Starting Odds
Clinical trial initiation • 25%
Regulatory approval • 25%
New program announcement • 25%
No major milestone • 25%
Official announcements from Sarepta or Arrowhead Pharmaceuticals
Story
Sarepta and Arrowhead Pharmaceuticals Announce $825 Million siRNA Collaboration with $500 Million Upfront and $325 Million Equity
Nov 26, 2024, 12:11 PM
Sarepta Therapeutics has entered into a global licensing and collaboration agreement with Arrowhead Pharmaceuticals, focusing on multiple clinical and preclinical small interfering RNA (siRNA) programs. The deal is valued at $825 million, with Arrowhead set to receive $500 million upfront and an additional $325 million through equity investment at a 35% premium. This partnership allows Sarepta to diversify its research beyond its traditional focus on Duchenne muscular dystrophy (DMD) to include fibrosis and neurological conditions. The collaboration includes several specific programs, such as ARO-DUX4 for facioscapulohumeral muscular dystrophy and ARO-MMP7 for idiopathic pulmonary fibrosis. The agreement reflects a growing trend of collaboration between biotech companies, as they seek to leverage each other's strengths in developing innovative therapies.
View original story
Similar markets
Major changes • 25%
Minor changes • 25%
No changes • 25%
Discontinues gene therapy • 25%
Relationship improves • 25%
Relationship deteriorates • 25%
Relationship remains the same • 25%
No official statement • 25%
Phase 2 Trial Completion • 25%
FDA Approval • 25%
Commercial Launch • 25%
None of the Above • 25%
Proof-of-concept data achieved • 25%
Partnership announcement • 25%
Regulatory approval submission • 25%
No major milestone achieved • 25%
Top 5 • 33%
Top 10 • 33%
Below top 10 • 33%
Phase 1 completion • 25%
Phase 2 completion • 25%
Phase 3 completion • 25%
No significant milestone • 25%
Significant progress • 25%
Moderate progress • 25%
Little progress • 25%
No progress • 25%